Novel oral anticoagulants (NOACs) are drugs approved for the prevention and treatment of many thromboembolic cardiovascular conditions as a safer alternative to warfarin. We reviewed studies published in PubMed(R), UpToDate(R), Web of Science(R), and Cochrane(R) about NOACs' risks and benefits in patients requiring anticoagulation, with a focus on gastrointestinal bleeding and on molecular and pathophysiological mechanisms underlying the risk of bleeding in patients treated with them. Apixaban resulted in a lower rate of gastrointestinal bleeding compared to dabigatran and rivaroxaban. However, data reported that gastrointestinal bleeding in patients treated with NOACs was less severe compared to warfarin. Studies show promising results on the increased and widespread use of NOACs in patients who require anticoagulation (for example-in case of atrial fibrillation or high risk of venous thromboembolism), reporting an overall lower risk of major bleeding events. The profile of NOACs was more effective and secure compared to warfarin, but a more careful medical prescription is required in patients who are at high risk of gastrointestinal bleeding.
Saviano, A., Brigida, M., Petruzziello, C., Candelli, M., Gabrielli, M., Ojetti, V., Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2022; 23 (22): N/A-N/A. [doi:10.3390/ijms232213955] [https://hdl.handle.net/10807/263335]
Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
Saviano, AngelaWriting – Original Draft Preparation
;Candelli, Marcello;Gabrielli, Maurizio;Ojetti, Veronica
2022
Abstract
Novel oral anticoagulants (NOACs) are drugs approved for the prevention and treatment of many thromboembolic cardiovascular conditions as a safer alternative to warfarin. We reviewed studies published in PubMed(R), UpToDate(R), Web of Science(R), and Cochrane(R) about NOACs' risks and benefits in patients requiring anticoagulation, with a focus on gastrointestinal bleeding and on molecular and pathophysiological mechanisms underlying the risk of bleeding in patients treated with them. Apixaban resulted in a lower rate of gastrointestinal bleeding compared to dabigatran and rivaroxaban. However, data reported that gastrointestinal bleeding in patients treated with NOACs was less severe compared to warfarin. Studies show promising results on the increased and widespread use of NOACs in patients who require anticoagulation (for example-in case of atrial fibrillation or high risk of venous thromboembolism), reporting an overall lower risk of major bleeding events. The profile of NOACs was more effective and secure compared to warfarin, but a more careful medical prescription is required in patients who are at high risk of gastrointestinal bleeding.File | Dimensione | Formato | |
---|---|---|---|
NOACS-ijms-23-13955.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
916.07 kB
Formato
Adobe PDF
|
916.07 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.